Market Exclusive

Analyst Activity – Cantor Fitzgerald Reiterates Buy on Arena Pharmaceuticals (NASDAQ:ARNA)

Analyst Ratings For Arena Pharmaceuticals (NASDAQ:ARNA)

Today, Cantor Fitzgerald reiterated its Buy rating on Arena Pharmaceuticals (NASDAQ:ARNA) with a price target of $37.00.

There are 2 hold ratings, 5 buy ratings on the stock.

The current consensus rating on Arena Pharmaceuticals (NASDAQ:ARNA) is Buy (Score: 2.71) with a consensus target price of $38.83 per share, a potential 54.78% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Arena Pharmaceuticals (NASDAQ:ARNA)
Arena Pharmaceuticals (NASDAQ:ARNA) has insider ownership of 1.88% and institutional ownership of 46.21%.

Recent Trading Activity for Arena Pharmaceuticals (NASDAQ:ARNA)
Shares of Arena Pharmaceuticals closed the previous trading session at with shares trading hands.

Exit mobile version